June 5, 2025
11 a.m. EDT

The field of Alzheimer’s Disease (AD) treatment is undergoing a transformative phase with recent drug approvals demonstrating the ability to slow cognitive decline in the early stages of the disease. These advancements mark a promising shift toward disease modification. However, they also emphasize the need for early detection and present new challenges in designing and conducting future clinical trials for AD. As these treatments gain traction in the affected patient population, drug developers must adopt strategic approaches to ensure successful trial outcomes.

In this webinar, our experts will explore recent AD drug approvals, diagnostic criteria and methods for early detection, and key operational considerations, such as enrolling preclinical and early-stage patients and evaluating how current treatments will impact future trial strategies.

This session will provide valuable insights for researchers and drug developers navigating the next chapter in AD treatment.

Attendees will gain insights into:

The evolving Alzheimer’s Disease treatment and regulatory landscape
Diagnostic criteria and early detection methods
Patient enrollment considerations, including preclinical participants
How recently approved drugs will impact the patient population and clinical trial design

Speakers:

Andreas Schreiner, MD – Senior Vice President, Medical Affairs, Neuroscience & Analgesia

Chris Foster, PhD – Senior Project Manager, Neuroscience